(NASDAQ: LGVN) Longeveron's forecast annual revenue growth rate of -5.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 63.47%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 6.63%.
Longeveron's revenue in 2023 is $767,000.On average, 2 Wall Street analysts forecast LGVN's revenue for 2023 to be $21,138,491, with the lowest LGVN revenue forecast at $18,525,868, and the highest LGVN revenue forecast at $23,751,113. On average, 2 Wall Street analysts forecast LGVN's revenue for 2024 to be $21,019,735, with the lowest LGVN revenue forecast at $11,400,534, and the highest LGVN revenue forecast at $30,638,936.
In 2025, LGVN is forecast to generate $4,750,223 in revenue, with the lowest revenue forecast at $4,750,223 and the highest revenue forecast at $4,750,223.